China Biopharma has announced that its partner, Soonfast Pharmaceutical Science & Technology, has successfully completed its trial production of a new antiviral product. This all-natural medicine has been approved in China for external use to treat human papillomavirus (HPV) and herpes simplex virus (HSV).
Tests have shown an inhibitory effect on the growth of HPV and HSV, and the medicine can reduce the infection from HPV and HSV up to 90 percent only in 2-3 days. Experiments have also proved that the herbal can kill all of the HPV types 6/11/16/18 and 33. The sample product is available for distributors now and the commercial product will be available next month.
According to the agreement reached with Soonfast in June this year, China Biopharma has the right to distribute this new all-natural antiviral medicine in overseas market. The successful trial production has now quickened some approval process for China Biopharma to launch commercial sales on overseas market including Europe and the US.
The company and Soonfast also plan to jointly conduct studies on its extracts in both China and the US so as to obtain approval necessary for selling this medicine as an over-the-counter drug. The company believes this new medicine would bring in significant revenue and profit in the near future once it is successfully introduced into the market.
China Biopharma is a fast-growing biopharmaceutical company based in China. Through its operating subsidiaries, the company develops and distributes biopharmaceutical and pharmaceutical products throughout China.